SCHEMBL22845489

SCHEMBL22845489

COc1ccc(CN2CCc3c(n4nc(Cc5ccccc5)cc4n(-c4ccccc4)c3=O)C2)cc1OC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GNRHR P30968 3/20 0.44
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
GAA P10253 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
MAPK1 P28482 2/20 0.40
HTT P42858 2/20 0.40
LMNA P02545 1/20 0.40
TSHR P16473 1/20 0.40
PDE4A P27815 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40
MAPT P10636 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TAAR1 Q96RJ0 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22845396 0.89 GNRHR (0.44) GNRHRKMT2AMEN1GAAL3MBTL1
SCHEMBL22845374 0.86 GNRHR (0.45) GNRHRKMT2AMEN1GAAL3MBTL1
SCHEMBL22845227 0.83 GNRHR (0.44) GNRHRKMT2AMEN1GAAL3MBTL1
SCHEMBL22845204 0.80 GNRHR (0.44) GNRHRKMT2AMEN1GAAL3MBTL1
SCHEMBL22845483 0.79 GNRHR (0.44) GNRHRKMT2AMEN1GAAL3MBTL1
SCHEMBL22845269 0.79 GNRHR (0.43) GNRHRKMT2AMEN1GAAL3MBTL1
SCHEMBL22845307 0.78 CLPP (0.47) GNRHRKMT2AMEN1GAAL3MBTL1
SCHEMBL22845403 0.75 TP53 (0.45) GNRHRKMT2AMEN1ALDH1A1LMNA
SCHEMBL22845487 0.72 HTR2C (0.38) GNRHRNPC1RAB9A
SCHEMBL9829278 0.69 KMT2A (0.58) KMT2AMEN1GAAL3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220000874-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2022-01-06 US disclosed
US-11136321-B2 Tricyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2021-10-05 US disclosed
US-20200407361-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2020-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220000874-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL GNRHR 2198/4885KMT2A 3917/4885MEN1 274/4885
US-11136321-B2 Tricyclic compounds SLC10A1, PKD1, CEL GNRHR 2198/4885KMT2A 3917/4885MEN1 274/4885
US-20200407361-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL GNRHR 2198/4885KMT2A 3917/4885MEN1 274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.